Erufosine
Erufosine is an inhibitor of PI3K/Akt and Ras/Raf/MAPK signaling pathways. Erufosine inhibits the activity of breast cancer cell lines MCF-7 and MDA-MB 231 (IC50: 40.95/40.8 μM) . Erufosine reduces the phosphorylation of PI3K (p85), Akt (PKB), and cRaf. Erufosine can be used in the study of breast cancer and myeloid leukemia[1].
Product Specifications
CAS Number
[202867-33-2]
Product Name Alternative
ErPC3; Erucylphosphohomocholine
UNSPSC
12352128
Target
Akt; p38 MAPK; PI3K; Raf; Ras
Related Pathways
GPCR/G Protein; MAPK/ERK Pathway; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
CCCCCCCC/C=C\CCCCCCCCCCCCOP(OCCC[N+](C)(C)C)([O-])=O
Molecular Formula
C28H58NO4P
Molecular Weight
503.74
References & Citations
[1]Dineva IK, et al. Erufosine suppresses breast cancer in vitro and in vivo for its activity on PI3K, c-Raf and Akt proteins. J Cancer Res Clin Oncol. 2012 Nov;138 (11) :1909-17.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1464557-01 0.02 mg (E-Coli)
Recombinant Porphyra yezoensis Putative DNA-directed RNA polymerase subunit omega (rpoZ)
Ask
View Details